UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to boost immune attack against HPV-driven head and neck cancer
Disease control OngoingThis phase 3 study tests whether adding an experimental immunotherapy (PDS0101) to standard pembrolizumab helps people with advanced HPV16-positive head and neck cancer live longer or delay cancer growth. About 252 participants will receive either the combination or pembrolizumab…
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated May 26, 2026 07:11 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat head and neck cancer
Disease control OngoingThis study tests a combination of two drugs—cetuximab and interleukin-12—in people with advanced head and neck cancer that has returned, spread, or cannot be removed by surgery. The goal is to find the safest dose of interleukin-12 and see if the pair can shrink tumors by helping…
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:01 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests two drugs, pembrolizumab and cabozantinib, in 36 people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination shrinks tumors and delays cancer growth. Participants receive both drugs intraven…
Matched conditions: UNRESECTABLE HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 07:01 UTC